Genfit (GNFT) has released an update.
Genfit, a biopharmaceutical company targeting rare liver diseases, has reported a stable cash position of €74.0 million as of Q1 2024, down from €128.6 million the previous year, with revenues of €1.1 million for the same quarter. This financial stability is expected to sustain the company into Q4 2025, underpinned by ongoing R&D efforts including a Phase 2 trial for ACLF and anticipated milestone revenues, including a significant commercial launch by Ipsen. Despite a decrease from the previous year, the company remains focused on advancing its diverse portfolio of R&D programs.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
